https://www.pharmaradar360.com/article/074307b21ae06ff6PharmaRadar360en2026-04-16T11:13:24.000ZClinical trials for medicines: guidance on compliance with ICH E6 good clinical practice (GCP) in the United Kingdomhttps://www.pharmaradar360.com/article/b88868728d7e8b22PharmaRadar360en2026-04-16T11:13:16.000ZClinical trials for medicines: guidance on quality and risk proportionalityhttps://www.pharmaradar360.com/article/450d8618e024178cPharmaRadar360en2026-04-16T11:00:00.000ZTiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Functionhttps://www.pharmaradar360.com/article/3273754290d33e5aPharmaRadar360en2026-04-16T10:45:00.000ZACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic healthhttps://www.pharmaradar360.com/article/ed7de102a9c63724PharmaRadar360en2026-04-16T09:37:10.000ZGuidance: Clinical trials for medicines: roles and responsibilitieshttps://www.pharmaradar360.com/article/18d42bac1298dcd5PharmaRadar360en2026-04-16T07:53:00.000ZΔήλωση Αποθεμάτων Φαρμάκων Ανθρώπινης Χρήσηςhttps://www.pharmaradar360.com/article/503c871cc1064f1cPharmaRadar360en2026-04-16T00:00:00.000ZEducational Initiatives for the Next Generation - Implementing Health Education for Elementary School Students and SDGs Education for Junior and Senior High School Students -https://www.pharmaradar360.com/article/44da77cd97aff82dPharmaRadar360en2026-04-16T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/a995621f587a12a1PharmaRadar360en2026-04-16T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/8e8bf26aa3d16880PharmaRadar360en2026-04-16T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/7f919f2ee0fae424PharmaRadar360en2026-04-16T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/d86f7d9f92736f59PharmaRadar360en2026-04-16T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/dd681e2df2b314a0PharmaRadar360en2026-04-16T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/8191b495ae148061PharmaRadar360en2026-04-16T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/ce2fc1f96bb48f09PharmaRadar360en2026-04-16T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/8eff9f7642f5f810PharmaRadar360en2026-04-16T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/dfe99c7c75fed461PharmaRadar360en2026-04-16T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/2872db32c209f737PharmaRadar360en2026-04-16T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/852bd78540e4c2efPharmaRadar360en2026-04-16T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/d42782e9e1edaf5dPharmaRadar360en2026-04-16T00:00:00.000Z6203https://www.pharmaradar360.com/article/3a59b9ee1de2ec9cPharmaRadar360en2026-04-16T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/26a07e73cc6109f3PharmaRadar360en2026-04-15T16:23:07.000ZTransparency data: MHRA annual accountability review minuteshttps://www.pharmaradar360.com/article/b18a0be282fe3028PharmaRadar360en2026-04-15T16:00:00.000ZFlow of Trump EOs slowing way downhttps://www.pharmaradar360.com/article/fe464bfc1b8e59cfPharmaRadar360en2026-04-15T14:47:07.000ZRecherche & industrie : le rêve d’une France souveraine, à l’épreuve des choixhttps://www.pharmaradar360.com/article/1a4e7d181c54aea3PharmaRadar360en2026-04-15T14:22:17.000ZGuillermo’s Story: Lessons from Patients’ Liveshttps://www.pharmaradar360.com/article/807b6a56e5f25513PharmaRadar360en2026-04-15T13:00:18.000ZGuidance: RSV Vaccine Factsheet – Information for Patients, Parents and Carershttps://www.pharmaradar360.com/article/3b3e01ca479e236bPharmaRadar360en2026-04-15T13:00:00.000ZMabwell announces Chinese clinical trial clearance for SST-001https://www.pharmaradar360.com/article/8ad067bbd6ed0af5PharmaRadar360en2026-04-15T12:00:00.000ZGSK completes acquisition of 35Pharma Inc.https://www.pharmaradar360.com/article/939026f5f828a35aPharmaRadar360en2026-04-15T12:00:00.000ZTeva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partnershttps://www.pharmaradar360.com/article/7177e24e9cd41075PharmaRadar360en2026-04-15T11:47:56.000ZActualizaciones del Código Alimentario Argentinohttps://www.pharmaradar360.com/article/cd88c9e34d444cb7PharmaRadar360en2026-04-15T10:57:09.000ZDecision: Medical devices given exceptional use authorisationshttps://www.pharmaradar360.com/article/22916c69ddcb62e8PharmaRadar360en2026-04-15T10:46:52.000ZΑνάκληση της παρτίδας EM1425 του καλλυντικού προϊόντος NEPTUNE AFTER SHAVEhttps://www.pharmaradar360.com/article/c13d21eecd4f9822PharmaRadar360en2026-04-15T10:41:52.000ZΑνάκληση της παρτίδας 333570 του συμπληρώματος διατροφής HEALTHAID HAEMOVIT, Liquid Gold Blackcurrant tastehttps://www.pharmaradar360.com/article/8adbe0eeac6882d5PharmaRadar360en2026-04-15T09:31:56.000ZReunión del Comité de Medicamentos Veterinarios de abril de 2026https://www.pharmaradar360.com/article/a252e6f707f9070aPharmaRadar360en2026-04-15T08:21:55.000ZDecision: Orphan registered medicinal productshttps://www.pharmaradar360.com/article/eb2205aa6a0440e9PharmaRadar360en2026-04-15T00:00:00.000Zneffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)https://www.pharmaradar360.com/article/2a1c3126fffbac79PharmaRadar360en2026-04-14T23:30:00.000ZAstellas Doses First Patient in Phase 3 Study of setidegrasib (ASP3082) for KRAS G12D-mutated Metastatic Pancreatic Ductal Adenocarcinomahttps://www.pharmaradar360.com/article/7d7f65e7d02e6b4fPharmaRadar360en2026-04-14T21:49:37.000ZManaging Financial Risk at the Site Level: Practical Strategies for Underfunded Studieshttps://www.pharmaradar360.com/article/f41d9ba053287168PharmaRadar360en2026-04-14T19:40:28.000ZThe Need for Clinical Research Sites to Transition to e-Regulatory Binders: Strategies, Pros, and Conshttps://www.pharmaradar360.com/article/8c00b29d0dc2078dPharmaRadar360en2026-04-14T19:39:59.000ZMeasuring Quality in the Age of AI: Why Regulatory Writing Needs a True Standardhttps://www.pharmaradar360.com/article/6a21ebd953e1aae1PharmaRadar360en2026-04-14T19:39:40.000ZEnhancing the Quality of Investigator-Initiated Trials Through Self-Study Moduleshttps://www.pharmaradar360.com/article/e61531582dc9971cPharmaRadar360en2026-04-14T19:39:11.000ZFrom Mapping Your Pathway to Traversing a Careerhttps://www.pharmaradar360.com/article/3e563006e0e75ea0PharmaRadar360en2026-04-14T19:38:47.000ZEmpowering Research-Naïve PIs for Complex and Advanced Therapeutic Trialshttps://www.pharmaradar360.com/article/a85065fe263b3bf3PharmaRadar360en2026-04-14T19:38:16.000ZThe Cost of Turnover in Clinical Operations: What Leaders Can Actually Do About Ithttps://www.pharmaradar360.com/article/2f015ef3d0b39a99PharmaRadar360en2026-04-14T19:37:56.000ZUsing AI to Unlock New Opportunities in Clinical Data Recruitment and Talent Developmenthttps://www.pharmaradar360.com/article/7ba7f079a8964dc6PharmaRadar360en2026-04-14T19:37:37.000ZA Practical Guide to Patient-Centric Trials Using Net Treatment Benefithttps://www.pharmaradar360.com/article/d05125a648bc87afPharmaRadar360en2026-04-14T19:37:18.000ZThe Recurring Conundrum of Diversity: Targeted Precision as an Economically Calculable Strategy